文献速递胸部肿瘤放疗放疗物理与技术

治疗相关淋巴细胞减少对晚期非小细胞肺癌免疫治疗的影响

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-08-30

该单中心回顾性研究纳入268例接受免疫治疗的晚期非小细胞肺癌患者,其中146例接受放疗,以绝对淋巴细胞计数<1000 cells/mm³定义淋巴细胞减少。围免疫治疗期淋巴细胞减少者无进展生存和总生存均显著更差,放疗显著增加淋巴细胞减少风险,多疗程、多照射部位和高剂量(≥50 Gy)与风险升高相关,立体定向体部放疗/放射外科降低风险。

要点

  • 围免疫治疗期淋巴细胞减少是晚期NSCLC免疫治疗患者PFS和OS的独立不良预后因素。
  • 多疗程、多照射部位和高剂量(≥50 Gy)增加放疗相关淋巴细胞减少风险,SBRT/放射外科降低风险。

核心结论

  • 淋巴细胞减少提示晚期非小细胞肺癌免疫治疗患者预后不良。
  • 淋巴细胞减少与更密集的放疗显著相关,选择合适放疗方案和技术可能对减少淋巴细胞减少至关重要。

研究设计与样本

  • 单中心回顾性研究,纳入268例接受免疫治疗的晚期非小细胞肺癌患者,其中146例接受放疗。
  • 淋巴细胞减少定义为绝对淋巴细胞计数<1000 cells/mm³,根据免疫治疗开始时或治疗期间是否存在围免疫治疗期淋巴细胞减少分为两组。

主要发现

  • 中位随访6.4个月,围免疫治疗期淋巴细胞减少患者(n=146,54.5%)的无进展生存显著更差(中位PFS:2.2 vs 5.9个月,P<.001)。
  • 围免疫治疗期淋巴细胞减少患者的总生存显著更差(中位OS:5.7 vs 12.1个月,P<.001)。
  • 多因素分析显示围免疫治疗期淋巴细胞减少仍是PFS和OS的显著预后因素。
  • 放疗显著增加围免疫治疗期淋巴细胞减少(OR 1.91,P=.025)。

关键数值与推荐

  • 淋巴细胞减少定义:绝对淋巴细胞计数<1000 cells/mm³。
  • 放疗相关淋巴细胞减少的危险因素:多疗程(OR 3.78,P<.001)、多照射部位(OR 4.77,P=.018)、较高剂量≥50 Gy(OR 3.75,P=.004)。
  • 立体定向体部放疗/放射外科降低放疗相关淋巴细胞减少风险(OR 0.21,P=.002)。

临床怎么用

  • 接受免疫治疗的晚期NSCLC患者应关注围免疫治疗期淋巴细胞计数,淋巴细胞减少提示预后不良。
  • 放疗计划时应考虑疗程数、照射部位数量和剂量对淋巴细胞减少的影响,优先选择SBRT/放射外科等可能减少淋巴细胞减少的技术。

局限性

  • 单中心回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT. METHODS AND METHODS: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000 cells/mm.3 Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy. RESULTS: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5%) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P < .001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P < .001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P = .025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P < .001), multiple irradiated sites (OR, 4.77; P = .018), and higher dose (≥50 Gy) (OR, 3.75; P = .004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P = .002). CONCLUSIONS: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Cho Y, Park S, Byun HK, et al. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31476418. doi:10.1016/j.ijrobp.2019.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。